That second green bird is me hearing the news that my cancer has become HER2+. A little over a year ago, you might have seen a lot of news about a new breast cancer treatment that adds 15 months of survival to a breast cancer survivor’s prognosis. It’s Genentech’s Perjeta, combined with Herceptin and chemotherapy.
Monday’s biopsy shows my cancer has decided to change into the kind of cancer that RESPONDS to this treatment.
Oh yeah! Oh yeah! That’s me! Oh yeah!
Here’s the another great piece of news. Genentech, the company that created Perjeta, has a co-pay program. So if my insurance doesn’t cover Perjeta (which, with this clinical record of success, they SHOULD, but it might NOT), Genentech will cover my expenses. I just pay a small $25 co-pay.
Novartis, the company that created Affinitor, does this as well. Novartis’ program allowed me to use Affinitor and it was the first treatment to work against my cancer.
So I’m feeling a bit pro-pharma this morning!!
I’ll post more details soon. Just wanted to get the word out. Looks like I might be around awhile!